Physician profile
Christopher S Smith
NPI 1538255476
$82,360.13
in general payments reported to CMS, 2019-2025
26 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $24K · 2023: $9,150 · 2024: $23K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $8,728 · Food and Beverage: $4,843 · Consulting Fee: $3,410 · Honoraria: $1,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,205.00 |
| Travel and Lodging | $8,727.74 |
| Food and Beverage | $4,842.75 |
| Consulting Fee | $3,410.00 |
| Honoraria | $1,680.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $24,375.27 | 2021-2024 | Epclusa |
| Phathom Pharmaceuticals, INC. | $18,451.23 | 2023-2025 | Voquezna, Voquezna Triple Pak, Voquezna Dual Pak |
| Madrigal Pharmaceuticals | $14,430.42 | 2024-2025 | Rezdiffra |
| Abbvie INC. | $13,114.95 | 2021-2025 | |
| Evoke Pharma, INC. | $6,267.91 | 2021-2023 | Gimoti |
| Intercept Pharmaceuticals, INC. | $3,510.32 | 2021-2024 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $396.89 | 2021-2023 | Entyvio, Gattex |
| Janssen Biotech, INC. | $278.64 | 2021-2023 | Stelara |
| Ironwood Pharmaceuticals, INC | $246.82 | 2021-2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.48 | 2021-2023 | Xifaxan |
| Si-Bone, INC. | $152.67 | 2022 | |
| Boston Scientific Corporation | $130.84 | 2024 | |
| Nestle Healthcare Nutrition INC. | $121.76 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $119.76 | 2021 | |
| Celgene Corporation | $108.32 | 2022-2024 | Zeposia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanara Medtech INC. | $101.50 | 2021 | |
| Merck Sharp & Dohme LLC | $65.77 | 2021-2022 | |
| Redhill Biopharma INC. | $65.16 | 2021-2023 | |
| Qol Medical, LLC | $43.22 | 2022 | |
| Ardelyx, INC. | $30.96 | 2022 | |
| Mallinckrodt Hospital Products INC. | $24.61 | 2022 | |
| Amgen INC. | $21.19 | 2023 | Avsola |
| Daiichi Sankyo INC. | $18.82 | 2021 | |
| Fresenius Kabi USA, LLC | $16.00 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $15.55 | 2021 | |
| Pfizer INC. | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.